Digestive Remedies in Belgium - New Market Study Published

The year 2015 was one of contrasts in digestive remedies on several levels. At first sight, it left a bitter taste for several categories and players. Paediatric digestive remedies suffered the consequences of the withdrawal of Motilium and Primperan, while H2 Blockers registered a significant double-digit value decline due to the lack of recognition of this product in Belgium. Antiflatulents waned by 2% in value and diarrhoeal remedies remained at a standstill in 2015. Finally, value sales of indigestion and heartburn remedies rose by 3% in 2015 but still did not take off in spite of the impressive media support from its leader, Reckitt Benckiser. Until the beginning of 2015, the offensive of digestive enzymes, proton pump inhibitors and traditional antacid brands, such as Gaviscon, was not sufficient to offset the significant decline of gastroprokinetics (included in antacids) over 2013/2014.

Competitive Landscape

It was inevitable that after the withdrawal of Motilium, the impressive decline of Janssen-Cilag left the field clear for its closest competitors. After having become co-leader in overall sales of digestive remedies in 2014, Boehringer Ingelheim captured the lead in digestive remedies in 2015 by achieving 11% of overall value sales. Due to the astonishing breakthrough of Buscopan Double Dose in IBS treatments over 2014/2015 – the company waited for 10 years before launching this novelty – Boehringer Ingelheim was the most dynamic player in actual value progression in 2015.

Full Report Details at
- http://www.fastmr.com/prod/1082219_digestive_remedies_belgium.aspx?afid=301

Industry Prospects

Opinions differ on the projected fortunes of digestive remedies over the forecast period. Some players believe it will continue to lick its wounds in the short term. The category should still cope with the anticipated strong decline in H2 blockers and paediatric digestive remedies and the lacklustre performance of laxatives, antiflatulents and diarrhoeal remedies. The niche category of proton pump inhibitors (sometimes called "third-generation antacids"), which brought a breath of fresh air to the category, is not expected to establish itself sustainably in the Belgian market. This should be an opportunity for non-gastroprokinetic antacids. However, volume sales still did not seem to take off in 2015 in spite of the beginning of a slowdown in proton pump inhibitors and renewed media support from Reckitt Benckiser for Gaviscon.

Report Overview

Discover the latest market trends and uncover sources of future market growth for the Digestive Remedies industry in Belgium with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Digestive Remedies in the United Arab Emirates
- Digestive Remedies in Finland
- Digestive Remedies in South Korea
- Digestive Remedies in Mexico
- Digestive Remedies in Tunisia